Genomic Vision Attended the 20th Edition of the European Drug Discovery Innovation Programme in Barcelona
18 Septembre 2023 - 6:30PM
Business Wire
- The event highlighted the rising importance of artificial
intelligence (AI) and machine learning (ML) in drug
discovery.
- Genomic Vision actively engaged in networking, fostering new
customers interested in GV technology and its applications in
general.
- Genomic Vision's Replication Combing Assay (RCA) aligns with
evolving biotech trends, reaffirming its commitment to advancing
drug discovery and pharmaceutical efficiency.
Regulatory News:
Genomic Vision (FR0011799907 – GV, – the “Company”), a
Euronext-listed biotechnology company that develops products and
services for the highly accurate characterization of DNA sequences,
was delighted to take part in the 20th Edition of the European Drug
Discovery Innovation Programme held in Barcelona on September 12th
and 13th.
This prominent event provided an invaluable opportunity for
Genomic Vision's teams to reinforce a comprehensive understanding
of customer demands in the quickly evolving pharmaceutical
environment. It became evident that there is a very significant
interest in artificial intelligence (AI) and machine learning (ML)
within the drug discovery pipeline, highlighting their growing
impact and importance in the industry.
During this event, Genomic Vision engaged in meaningful
interactions, fostering new interested customer, and participating
in professional discussions. The company had the privilege of
attending several highly informative conferences on the subject of
AI and ML in drug discovery. These sessions were fully in line with
Genomic Vision's commitment to staying at the front of the
technology advancements and positioning itself as a key player in
this dynamic industry.
Indeed, Genomic Vision's innovative technology and its diverse
range of applications are clearly associated with the evolving
trends in biotechnology and the future of drug research. The
company's participation in this event reaffirmed its dedication to
facilitating advancements in drug discovery and enhancing the
efficiency of pharmaceutical industry.
Yann BENUREAU, Senior Scientist at Genomic Vision, said:
“This event gave us the opportunity to showcase our technology and
observe the keen interest it has generated in the scientific
community to shape the future of drug discovery. Our commitment to
continuous adaptation and innovation remains unwavering as we
strive to meet the evolving needs of our customers and the
pharmaceutical industry as a whole.”
ABOUT THE EUROPEAN DRUG DISCOVERY INNOVATION
PROGRAMME
The European Drug Discovery Innovation Programme is a prominent
event in the field of pharmaceutical research in Europe. It brings
together experts, researchers, and industry professionals to
discuss the latest advancements, innovations and trends in drug
discovery. This event provides a platform for knowledge exchange,
professional networking, and thorough discussions on topics such as
artificial intelligence, machine learning, and other technological
advancements crucial to the future of pharmaceutical research. It
represents a significant opportunity for companies and researchers
to stay at the forefront of innovation and contribute to the
ongoing improvement of medical treatments.
ABOUT GENOMIC VISION
GENOMIC VISION is a biotechnology company that develops products
and services for the highly accurate characterization of genome
modifications. We deliver high-quality integrated genomic analysis
solutions to improve quality control and bioproduction standards of
advanced gene therapies at scale. Based on molecular combing
technology and artificial intelligence, The Company provides robust
quantitative measurements needed for high confidence
characterization of transformed cell lines and prediction of cell
line performance, in particular in the context of the
biomanufacturing processes of cell and gene therapies. Genomic
Vision’s molecular combing technology has further applications in
drug development of agents targeting DNA replication and damage
response mechanisms, visualizing DNA replication kinetics and
telomere length maintenance. Genomic Vision, based near Paris in
Bagneux, is a public company listed in compartment C of Euronext’s
regulated market in Paris (Euronext: GV – ISIN: FR0011799907).
For further information, please visit www.genomicvision.com
Member of the CAC® Mid & Small and CAC® All-Tradable
indices
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business. Such forward-looking statements are based on assumptions
that Genomic Vision considers to be reasonable. However, there can
be no assurance that such forward-looking statements will be
verified, which statements are subject to numerous risks, including
the risks set forth in the “Risk Factors” section of the universal
registration document filed with the AMF on April 28, 2023 under
number D.23-0383, available on the web site of Genomic Vision
(www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
Genomic Vision has set up a financing line in the form of
convertible notes with warrants (OCABSA) with its Financing
partner. The shares resulting from the conversion or exercise of
the aforementioned securities will, in general, be sold on the
market, which could create downward pressure on the share price as
well as a dilution. Shareholders could therefore suffer a loss of
their invested capital due to a significant decrease in the value
of the company's shares. The company has carried out several
dilutive financing operations, and investors are advised to be very
careful before making a decision to invest in the company's
securities.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230918843917/en/
Genomic Vision Aaron Bensimon Chairman of the Management
Board Tel.: +33 1 49 08 07 51 investisseurs@genomicvision.com
Ulysse Communication Media Relations Bruno Arabian Tel.:
+33 1 42 68 29 70 barabian@ulysse-communication.com
Consilium Strategic Communications International Investor
Relations & Strategic Communications Tel.: +44 (0) 20 3709 5700
GenomicVision@consilium-comms.com
NewCap France Investor Relations & Strategic
Communications Tel.: +33 1 44 71 94 94 gv@newcap.eu
Guerrero Ventures (TSXV:GV)
Graphique Historique de l'Action
De Oct 2024 à Nov 2024
Guerrero Ventures (TSXV:GV)
Graphique Historique de l'Action
De Nov 2023 à Nov 2024